grade
pharmaceutical primary standard
API family
rivastigmine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N([C@@H](C)c1cc(ccc1)OC(=O)N(CC)C)(C)C.O[C@@H]([C@H](O)C(=O)O)C(=O)O
InChI
1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1
InChI key
GWHQHAUAXRMMOT-RWALOXMOSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Rivastigmine hydrogen tartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
卡巴拉汀是一种口服、脑透过性、可逆的胆碱酯酶抑制剂。
卡巴拉汀是一种口服口服、脑透过性、可逆的胆碱酯酶抑制剂，可增强阿尔茨海默症和帕金森氏病患者的认知功能。卡巴拉汀可同时抑制丁酰胆碱酯酶和乙酰胆碱酯酶。
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 重酒石酸卡巴拉汀
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Aquatic Chronic 2
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Carina Wattmo et al.
Clinical interventions in aging, 8, 329-339 (2013-05-18)
To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD). This 3-year, prospective, multicenter study included 880
Galeno Rojas et al.
Medicina, 73(3), 213-223 (2013-06-05)
Cognitive impairment and dementia treatment costs are significant for health systems. According to national and international guidelines, recommended drugs for treatment of dementias are cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Despite these guidelines recommendations, other nootropics, vasodilators and antioxidants
Agadi Hiremath Thippeswamy et al.
Journal of acupuncture and meridian studies, 6(4), 208-213 (2013-08-27)
The objective of this study was to evaluate the synergistic activity of Bacopa monniera with Rivastigmine against aluminum-chloride (AlCl3)-induced cognitive impairment in rats. Adult male Wistar rats were divided into ten groups (n = 10) and subjected to their assigned
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0001516 | 04061833808276 |